Back

Concomitant hypertension in hypertrophic cardiomyopathy: cardiovascular magnetic resonance biomarkers to guide cardiovascular prevention

29 August 2026 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Personalised risk assessment with cardiac magnetic resonance: integrating perfusion, fibrosis, and phenotype Late Gadolinium Enhancement ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Jeremy Florence

Hospital Lariboisiere, Paris (France)

6 More presentations in this session

Presentation thumbnail
Prognostic value of stress perfusion CMR: a real-world single-center experience in portuguese patients with known coronary artery disease
Doctor M. Sobral Domingues (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Prognostic value of stress perfusion CMR in patients without known coronary artery disease: a real-world single-center experience
Doctor M. Sobral Domingues (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Prognostic impact of late gadolinium enhancement granularity using cardiovascular magnetic resonance in end‑stage hypertrophic cardiomyopathy
Doctor J. Hudelo (Paris, FR)
Abstract Slides
Presentation thumbnail
One size does not fit all: rethinking the 15-mm threshold in hypertrophic cardiomyopathy
Ms M. Souto (Aracaju, BR)
Abstract Slides Video
Presentation thumbnail
Avoiding overdiagnosis of hypertrophic cardiomyopathy: a CMR–based diagnostic strategy for ventricular septal bulge
Doctor M. Panelo (Barcelona, ES)
Abstract Slides

Access the full session

Session thumbnail
Personalised risk assessment with cardiac magnetic resonance: integrating perfusion, fibrosis, and phenotype

The Event

Event poster

ESC Congress 2026

29 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular magnetic resonance late gadolinium enhancement risk score for mortality in hypertrophic cardiomyopathy: the HCM-LGE risk score
1 September 2025
thumbnail
Congress Presentation
Coexistent diabetes is associated with the presence of adverse phenotypic features in patients with hypertrophic cardiomyopathy
26 August 2022
thumbnail
Congress Presentation
Assessment of hypertensive heart disease: when to perform a cardiac MR?
27 August 2023
thumbnail
Congress Presentation
The effect of eplerenone on fibrosis in hypertrophic cardiomyopathy. A randomised controlled trial assessed using cardiopulmonary exercise testing and cardiovascular magnetic resonance
1 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources